EicOsis LLC Profile last edited on: 1/17/2018
CAGE: 6TV05
UEI: EM8CCFVCTV69
Business Identifier: Safe and effective, non-narcotic therapies for moderate to severe pain and inflammation 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 03
County: Yolo
Congr. District: 03
County: Yolo
Public Profile
EicOsis is developing a first-in-class therapy of a once daily, oral treatment for neuropathic and inflammatory pain in humans and animals: non-opioid therapeutics. Pain is an enormous emotional and economic burden. Current therapies have dose limiting side effects in addition to being ineffective in more than 3 of 4 patients. EicOsis discovered a novel enzyme target to alleviate pain without the dose limiting or narcotic side effects that exist in current treatments.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2022 | 1 | NIH | $279,136 | |
| Project Title: Identification of mechanism-based therapies to treat arrhythmogenic cardiomyopathy by resolving perturbations in regulatory lipid signaling | ||||
| 2019 | 1 | NIH | $268,196 | |
| Project Title: Inhibiting Soluble Epoxide Hydrolase as a Treatment for Chemotherapy Inducedperipheral Neuropathic Pain | ||||
| 2017 | 2 | NIH | $1,740,305 | |
| Project Title: sEH Inhibitors to Treat Neuropathic Pain | ||||
Key People / Management
Bruce Hammock -- Founder and CEO
Gilles Attia -- Legal Advisor
Alan R Buckpitt -- Vice President of Pharmacology
Irene Cortespuch
Bora Inceoglu -- Vice President of Research
Cindy McReynolds -- Project Manager
William Schmidt -- Clinical Development
Karen Wagner -- Principal Scientist
Gilles Attia -- Legal Advisor
Alan R Buckpitt -- Vice President of Pharmacology
Irene Cortespuch
Bora Inceoglu -- Vice President of Research
Cindy McReynolds -- Project Manager
William Schmidt -- Clinical Development
Karen Wagner -- Principal Scientist
